Cargando…
A Reduction in ADAM17 Expression Is Involved in the Protective Effect of the PPAR-α Activator Fenofibrate on Pressure Overload-Induced Cardiac Hypertrophy
The peroxisome proliferator-activated receptor-α (PPAR-α) agonist fenofibrate ameliorates cardiac hypertrophy; however, its mechanism of action has not been completely determined. Our previous study indicated that a disintegrin and metalloproteinase-17 (ADAM17) is required for angiotensin II-induced...
Autores principales: | Zeng, Si-Yu, Lu, Hui-Qin, Yan, Qiu-Jiang, Zou, Jian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6076894/ https://www.ncbi.nlm.nih.gov/pubmed/30105051 http://dx.doi.org/10.1155/2018/7916953 |
Ejemplares similares
-
HMGB1 Is Involved in the Protective Effect of the PPARα Agonist Fenofibrate against Cardiac Hypertrophy
por: Jia, Zhankui, et al.
Publicado: (2014) -
Rutaecarpine prevents hypertensive cardiac hypertrophy involving the inhibition of Nox4‐ROS‐ADAM17 pathway
por: Zeng, Si‐yu, et al.
Publicado: (2018) -
Microtubule Stabilization in Pressure Overload Cardiac Hypertrophy
por: Sato, Hiroshi, et al.
Publicado: (1997) -
Bezafibrate Attenuates Pressure Overload-Induced Cardiac Hypertrophy and Fibrosis
por: Xu, Si-Chi, et al.
Publicado: (2017) -
Activation of transient receptor potential vanilloid 4 is involved in pressure overload-induced cardiac hypertrophy
por: Zou, Yan, et al.
Publicado: (2022)